Cargando…
Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients
The increasing use of technological devices for the management of diabetes is related to the prolonged exposure of patients’ skin to chemical and mechanical agents and, consequently, to the increased risk of developing dermatological complications. Among these, contact dermatitis is the most insidio...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965381/ https://www.ncbi.nlm.nih.gov/pubmed/35370980 http://dx.doi.org/10.3389/fendo.2022.846137 |
_version_ | 1784678420762853376 |
---|---|
author | Passanisi, Stefano Salzano, Giuseppina Galletta, Francesca Aramnejad, Sara Caminiti, Lucia Pajno, Giovanni B. Lombardo, Fortunato |
author_facet | Passanisi, Stefano Salzano, Giuseppina Galletta, Francesca Aramnejad, Sara Caminiti, Lucia Pajno, Giovanni B. Lombardo, Fortunato |
author_sort | Passanisi, Stefano |
collection | PubMed |
description | The increasing use of technological devices for the management of diabetes is related to the prolonged exposure of patients’ skin to chemical and mechanical agents and, consequently, to the increased risk of developing dermatological complications. Among these, contact dermatitis is the most insidious skin disorder. Despite the magnitude of the issue, no universally accepted recommendations on the management of this common complication are currently available. Our observational study aimed to describe all the solutions adopted by patients and their caregivers to treat and prevent the appearance of contact dermatitis and to describe the clinical impact of this cutaneous complication. Twenty-one pediatric patients (mean age 12.1 ± 3.7 years) with type 1 diabetes were recruited in the study. The most common treatment used to treat acute skin lesions was the application of topical corticosteroids, sometimes associated with topical antibiotics (9.5%). In order to prevent the further appearance of dermatitis, the most frequently adopted measure was the use of hydrocolloid and/or silicone-based adhesives, followed by the application of protective barrier films. One patient reported benefit from the off-label use of fluticasone propionate nasal spray. However, only 52.4% of the study participants achieved a definitive resolution of the skin issue, and 38.1% of patients were forced to discontinue insulin pump therapy and/or continuous glucose monitoring. No differences were observed in glycated hemoglobin values between the period before and after the onset of contact dermatitis. Our study confirms the severity of this dermatological complication that may hinder the spread of new technologies for the management of diabetes. Finally, our findings highlight the importance of establishing close collaboration both with pediatric allergy specialists to prescribe the most suitable treatment and with manufacturing companies to ensure that adhesives of technological devices are free of harmful well-known sensitizers. |
format | Online Article Text |
id | pubmed-8965381 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89653812022-03-31 Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients Passanisi, Stefano Salzano, Giuseppina Galletta, Francesca Aramnejad, Sara Caminiti, Lucia Pajno, Giovanni B. Lombardo, Fortunato Front Endocrinol (Lausanne) Endocrinology The increasing use of technological devices for the management of diabetes is related to the prolonged exposure of patients’ skin to chemical and mechanical agents and, consequently, to the increased risk of developing dermatological complications. Among these, contact dermatitis is the most insidious skin disorder. Despite the magnitude of the issue, no universally accepted recommendations on the management of this common complication are currently available. Our observational study aimed to describe all the solutions adopted by patients and their caregivers to treat and prevent the appearance of contact dermatitis and to describe the clinical impact of this cutaneous complication. Twenty-one pediatric patients (mean age 12.1 ± 3.7 years) with type 1 diabetes were recruited in the study. The most common treatment used to treat acute skin lesions was the application of topical corticosteroids, sometimes associated with topical antibiotics (9.5%). In order to prevent the further appearance of dermatitis, the most frequently adopted measure was the use of hydrocolloid and/or silicone-based adhesives, followed by the application of protective barrier films. One patient reported benefit from the off-label use of fluticasone propionate nasal spray. However, only 52.4% of the study participants achieved a definitive resolution of the skin issue, and 38.1% of patients were forced to discontinue insulin pump therapy and/or continuous glucose monitoring. No differences were observed in glycated hemoglobin values between the period before and after the onset of contact dermatitis. Our study confirms the severity of this dermatological complication that may hinder the spread of new technologies for the management of diabetes. Finally, our findings highlight the importance of establishing close collaboration both with pediatric allergy specialists to prescribe the most suitable treatment and with manufacturing companies to ensure that adhesives of technological devices are free of harmful well-known sensitizers. Frontiers Media S.A. 2022-03-15 /pmc/articles/PMC8965381/ /pubmed/35370980 http://dx.doi.org/10.3389/fendo.2022.846137 Text en Copyright © 2022 Passanisi, Salzano, Galletta, Aramnejad, Caminiti, Pajno and Lombardo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Passanisi, Stefano Salzano, Giuseppina Galletta, Francesca Aramnejad, Sara Caminiti, Lucia Pajno, Giovanni B. Lombardo, Fortunato Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients |
title | Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients |
title_full | Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients |
title_fullStr | Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients |
title_full_unstemmed | Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients |
title_short | Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients |
title_sort | technologies for type 1 diabetes and contact dermatitis: therapeutic tools and clinical outcomes in a cohort of pediatric patients |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965381/ https://www.ncbi.nlm.nih.gov/pubmed/35370980 http://dx.doi.org/10.3389/fendo.2022.846137 |
work_keys_str_mv | AT passanisistefano technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients AT salzanogiuseppina technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients AT gallettafrancesca technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients AT aramnejadsara technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients AT caminitilucia technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients AT pajnogiovannib technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients AT lombardofortunato technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients |